Explore Peels, microneedling, PRP, Korean Glass Skin, and hair restoration
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
There are also no reported withdrawal symptoms
These drugs should now be further investigated as they could potentially be used to protect the salivary glands of patients undergoing radiation therapy
CJC 1295 with DAC (Drug Affinity Complex) has a much longer half-life, leading to a sustained elevation of GH levels, or a bleed. CJC 1295 without DAC (also known as Mod GRF 1-29) has a short half-life, creating a more natural, short pulse
